Ultragenyx Pharmaceu (RARE)

$22.91 +0.16 (0.70%)
Market Cap 2.20B
Revenue (ttm) 673.00M
Net Income (ttm) -575.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -85.44%
Debt to Equity Ratio 0.00
Volume 1,095,000
Avg Vol 2,983,412
Day's Range N/A - N/A
Shares Out 96.63M
Stochastic %K 70%
Beta 0.16
Analysts Strong Sell
Price Target $56.55

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
SuperGreenToday
SuperGreenToday Feb. 25 at 7:16 PM
$RARE Share Price: $22.80 Contract Selected: Aug 21, 2026 $17.5 Calls Buy Zone: $6.71 – $8.29 Target Zone: $12.58 – $15.37 Potential Upside: 77% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 24 at 8:21 PM
$RARE shows building momentum on 1D as RSI climbs. While 1W remains neutral, 4H and 30M CCI indicate short-term strength. Despite legal headlines, technical signals suggest a shift toward a more constructive mid-term structure. @DailyAnalysis
0 · Reply
SaTwits
SaTwits Feb. 24 at 6:24 AM
$RARE getting them to print in Aug
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 23 at 8:48 PM
$RARE $CRSP $NTLA $BMRN $BBIO
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 23 at 8:29 PM
$RARE shows building momentum on 1D as RSI climbs. While 1W remains neutral, 4H and 30M CCI indicate short-term strength. Despite legal headlines, technical signals suggest a shift toward a more constructive mid-term structure. @DailyAnalysis
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 23 at 6:29 PM
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder $RARE $VTI $XBI https://stocktwits.com/news/equity/markets/rare-stock-edges-up-on-priority-review-for-gene-therapy-in-rare-metabolic-disorder/cZRtz9oR4yr
0 · Reply
notreload_ai
notreload_ai Feb. 23 at 4:07 PM
$RARE one-time gene therapy DTX401 just got FDA Priority Review for Glycogen Storage Disease Type Ia (GSDIa). Possible approval by August 23, 2026 – the first treatment that could fix the root cause instead of just managing symptoms. https://notreload.xyz/fda-priority-review-for-dtx401-gene-therapy-in-gsdia/
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 22 at 6:45 PM
$RARE shows building momentum on 1D as RSI climbs. While 1W remains neutral, 4H and 30M CCI indicate short-term strength. Despite legal headlines, technical signals suggest a shift toward a more constructive mid-term structure. @DailyAnalysis
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 21 at 10:06 PM
$RARE is deeply oversold on 1D RSI following clinical updates. The 1W chart shows value, but wait for 4H STOCH to confirm a trend shift. Watch 30M CCI for signs of a relief rally. @DailyAnalysis
0 · Reply
Kwazimoto
Kwazimoto Feb. 20 at 7:50 PM
$RARE had such good
0 · Reply
Latest News on RARE
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 24, 2026, 9:11 AM EST - 1 day ago

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Ultragenyx to Participate at Investor Conferences in March

Feb 23, 2026, 4:30 PM EST - 2 days ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Feb 23, 2026, 8:30 AM EST - 2 days ago

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 20, 2026, 4:30 PM EST - 5 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Feb 18, 2026, 2:07 PM EST - 7 days ago

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript

Feb 13, 2026, 6:47 PM EST - 12 days ago

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript

Why Is Ultragenyx Stock Sinking Friday?

Feb 13, 2026, 1:21 PM EST - 12 days ago

Why Is Ultragenyx Stock Sinking Friday?

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Feb 12, 2026, 4:01 PM EST - 13 days ago

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical

Feb 9, 2026, 4:30 PM EST - 16 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Feb 9, 2026, 3:01 AM EST - 17 days ago

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Feb 3, 2026, 8:00 AM EST - 22 days ago

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Jan 30, 2026, 8:30 AM EST - 26 days ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Jan 23, 2026, 2:05 PM EST - 4 weeks ago

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline

Jan 22, 2026, 6:01 AM EST - 4 weeks ago

Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline

Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:55 PM EST - 6 weeks ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 6 weeks ago

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Dec 30, 2025, 4:05 PM EST - 2 months ago

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Dec 30, 2025, 2:24 PM EST - 2 months ago

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

Dec 30, 2025, 9:52 AM EST - 2 months ago

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dec 29, 2025, 1:05 PM EST - 2 months ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

MREO

Ultragenyx's bone disease drug fails late-stage trials

Dec 29, 2025, 8:35 AM EST - 2 months ago

Ultragenyx's bone disease drug fails late-stage trials

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Dec 29, 2025, 8:30 AM EST - 2 months ago

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

Dec 14, 2025, 11:30 PM EST - 2 months ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ABBV ALGT CGNX COHR EOLS INSP LTH

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 3:23 PM EST - 3 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 3:13 AM EST - 3 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 12:26 AM EST - 4 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Nov 4, 2025, 4:01 PM EST - 4 months ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 4:30 PM EDT - 4 months ago

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Sep 30, 2025, 4:05 PM EDT - 5 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 10:13 AM EDT - 5 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 12:17 PM EDT - 6 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Sep 8, 2025, 4:05 PM EDT - 6 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 2:27 PM EDT - 6 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript

Ultragenyx to Participate at Investor Conferences in September

Aug 29, 2025, 4:30 PM EDT - 6 months ago

Ultragenyx to Participate at Investor Conferences in September

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Aug 18, 2025, 8:00 AM EDT - 6 months ago

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 12:42 AM EDT - 7 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 5, 2025, 4:01 PM EDT - 7 months ago

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Jul 30, 2025, 8:30 AM EDT - 7 months ago

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

SuperGreenToday
SuperGreenToday Feb. 25 at 7:16 PM
$RARE Share Price: $22.80 Contract Selected: Aug 21, 2026 $17.5 Calls Buy Zone: $6.71 – $8.29 Target Zone: $12.58 – $15.37 Potential Upside: 77% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 24 at 8:21 PM
$RARE shows building momentum on 1D as RSI climbs. While 1W remains neutral, 4H and 30M CCI indicate short-term strength. Despite legal headlines, technical signals suggest a shift toward a more constructive mid-term structure. @DailyAnalysis
0 · Reply
SaTwits
SaTwits Feb. 24 at 6:24 AM
$RARE getting them to print in Aug
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 23 at 8:48 PM
$RARE $CRSP $NTLA $BMRN $BBIO
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 23 at 8:29 PM
$RARE shows building momentum on 1D as RSI climbs. While 1W remains neutral, 4H and 30M CCI indicate short-term strength. Despite legal headlines, technical signals suggest a shift toward a more constructive mid-term structure. @DailyAnalysis
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 23 at 6:29 PM
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder $RARE $VTI $XBI https://stocktwits.com/news/equity/markets/rare-stock-edges-up-on-priority-review-for-gene-therapy-in-rare-metabolic-disorder/cZRtz9oR4yr
0 · Reply
notreload_ai
notreload_ai Feb. 23 at 4:07 PM
$RARE one-time gene therapy DTX401 just got FDA Priority Review for Glycogen Storage Disease Type Ia (GSDIa). Possible approval by August 23, 2026 – the first treatment that could fix the root cause instead of just managing symptoms. https://notreload.xyz/fda-priority-review-for-dtx401-gene-therapy-in-gsdia/
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 22 at 6:45 PM
$RARE shows building momentum on 1D as RSI climbs. While 1W remains neutral, 4H and 30M CCI indicate short-term strength. Despite legal headlines, technical signals suggest a shift toward a more constructive mid-term structure. @DailyAnalysis
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 21 at 10:06 PM
$RARE is deeply oversold on 1D RSI following clinical updates. The 1W chart shows value, but wait for 4H STOCH to confirm a trend shift. Watch 30M CCI for signs of a relief rally. @DailyAnalysis
0 · Reply
Kwazimoto
Kwazimoto Feb. 20 at 7:50 PM
$RARE had such good
0 · Reply
d_risk
d_risk Feb. 19 at 4:03 AM
$RARE - Ultragenyx Pharmaceutical Inc - 10K - Updated Risk Factors RARE’s risk profile tightens around regulatory and political volatility: failed UX143 Phase 3s and a CRL for UX111 drive restructuring and expense cuts; evolving FDA standards, Chevron’s overruling, new executive orders, MFN drug pricing moves, heightened FDA scrutiny of manufacturing (including China), shifting tariffs, AI/data/privacy rules, social media liability, and workforce reduction all add fresh uncertainty to approvals, costs, timelines, and competitiveness. #GeneTherapy #RegulatoryRisks #DrugPricingPolicies #WorkforceRestructuring #Biopharmaceuticals #RegulatoryRisk #DrugPricing #ManufacturingScrutiny #PoliticalVolatility 🟢 Added 🟠 Removed https://d-risk.ai/RARE/10-K/2026-02-18
0 · Reply
BioSpecialOne
BioSpecialOne Feb. 18 at 4:45 PM
$RARE lookin for a good entry point here. Any watchers here? let me know what do you think...
2 · Reply
Kwazimoto
Kwazimoto Feb. 18 at 3:09 PM
$RARE please just one green day
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 18 at 2:55 AM
$OCUL $ALVO VSTM/TLX & $RARE all trading at or near 4.5 month lows Should OCUL have accepted Sanofi's $16/share offer last September? If anyone is aware of any comm'l-stage bio that has rewarded shareholders for refusing a buyout please share. We are unaware of even 1. Allegedly Novartis was close to an offer for $CYTK at ~$100/sh+ 13 months ago ALVO: same fate at $CHRS which got multiple biosimilars across the finish line, but is now focused on oncology? Mr. Lanfear? ​RARE: 3 big late-stage pipeline fails in a row (excl DTX401)? Only 9 of 171 new comm'l-stage non-oncology focused bios since 1/1/13 provided meaningful shareholders gains post approval excl M&A (0 of 61 in oncology excl M&A). The evidence is overwhelming shareholder value of comm'l-stage bios like RARE is maximized via M&A exit. They happen but are rare no pun intended...the odds are too long for multiple approvals. Attached are all comm'l-stage bios <10% above 4.5 mo lows O/c we could be proven wrong. For entertainment only.
2 · Reply
Kwazimoto
Kwazimoto Feb. 17 at 7:30 PM
$RARE why is every purchase just sold instantly?
0 · Reply
Puffyk
Puffyk Feb. 17 at 6:51 PM
4 Years This Will Be $500/Share and touch $125-$150 This Year. $RARE earth minerals are needed in all our technology and chips. Eric Sprott one of the biggest investors in the world continues to buy this stock on the tens of millions. They have eliminated all debt. Drilling exploration continues and they keep finding more and more silver and gold and they have not even tapped into the other areas. Look at the gold and silver prices and what the projections are over the next 5 years. It is simply match. This is an INVESTMENT right here in the USA. Take 18 minutes and you will get ALL YOUR ANSWERS. https://youtu.be/Qs6ztLcbL9Y?si=ph3JyxctHn9PSj-0
0 · Reply
bizness1957
bizness1957 Feb. 17 at 6:50 PM
$RARE breaking out
0 · Reply
Kwazimoto
Kwazimoto Feb. 17 at 2:57 PM
$RARE would love that 7M volume again like we had on Friday
0 · Reply
jw56502
jw56502 Feb. 14 at 4:25 PM
$RARE Q2 cc was actually OK: Negative: 1. UX143 P3 failure and ligering effects of doubt on this management + future study/drug designs (and uncertainty of FDA scrutiny on rare decease drugs/approval designs). 2. UX111 IRL on the CRL response = delays. 3. Burn rate is to high and not sustainable. Positive (and need to execute this year) 1. 2026 2 PDUFAs/possible approvals (UX111 and DTX401) 2. These indications are small, however, pricing will be +1m and above (I have in my notes between 2-4m) 3. UX111 IRL is only related to manufacturing documentation and not safety or the drug itself (a hurdle they can overcome). 4. Restructure and show the Market they are in control of RD costs. Actually, the GM is 90% and RD + Sales they can control/influence directly. They have 700m cash. 5. Upon drug aproval this year they should reccieved PRVs. 6. Base business is chugging along and only a little uneven ordering from Brazil is causing a minor nusance on this years revenue.
0 · Reply
Kwazimoto
Kwazimoto Feb. 13 at 8:00 PM
$RARE this is just getting ridiculous at this point
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 6:33 PM
$RARE RSI: 29.79, MACD: -0.9061 Vol: 0.93, MA20: 23.83, MA50: 27.51 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kwazimoto
Kwazimoto Feb. 13 at 5:59 PM
$RARE somebody is really trying to keep this down
0 · Reply